Applied Genetic Technologies Corporation

AGTC (NASDAQ: AGTC), Is a biotechnology company founded in 1999 in Florida, United States. The main focus of the research is generic diseases related to the eye Or in medical terms ophthalmologic genetic diseases.

The company has the expertise and technology to help cure diseases like achromatopsia, retinoschisis, retinitis pigmentosa, and age-related macular degeneration, in other words, cure blindness through genetic engineering.

It is working with Bionic Sight since 2017 on the field of Optogenetics and Retinal Coding. Bionic Sight is a technology company that develops optogenetic gene therapy vectors and devices to treat retinal degenerative diseases. So the Gene Therapy, Ophthalmologic Genetic Engineering of AGTC combined with Optogenetics together are achieving wonders!

On January 9, 2020, they reported positive results from a Phase 1 (of 2) trial for its investigational gene therapy for retinitis pigmentosa and they were positive and promising. Unfortunately, come march, further doses were not administered to new patients due to Covid-19 in Late Feb/Early March 2020. A few weeks later, they published data from the dose-escalation cohorts of its ongoing Phase 1/2 clinical programs in patients with Achromatopsia due to various mutations.

At the time of posting this article, the ticket AGTC is trading at

Just like any other research company, until the moment they announce their products after successful trials and FDA approvals and acceptance in the biotech community, this company too has more expenses than profits, their balances sheets might look like they are spending more than they should and are not profitable yet, but that is the goal. The goal is to get as much funding during the research stage and then once the research is successful, you sow the rewards of the research.

Out of the 8 analysts, over the past 4 months Starting from December 2020 to March 2021, the majority is recommending to buy this growth stock and in March 20201, 3 of the 6 analysts recommend hold. None of them is recommending to Sell.

AGTC went up to $9 and for good reasons. Institutional Ownership increased and bettered the overall outlook and confidence, price targets were upgraded, making them more achievable, clinical trials were positive, award recognition, and huge cash at hand. It has been trading low since then for no reason other than the overall market had been bumpy since last week.

Disclaimer: I am not a professional or licensed CPA or tax attorney. Please discuss this with your CPA or attorney before anything. This is just for information purposes and gives you a topic worth discussing with your CPA/Attorney.